NCT06932471View on ClinicalTrials.gov

Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

PHASE3RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

MY008211A tablets

MY008211A tablets Participants will receive MY008211A at a dose of 400 mg orally b.i.d

Trial Locations (1)

100032

RECRUITING

Peking Union Medical College Hospital (PUMCH)., Beijing

All Listed Sponsors
lead

Wuhan Createrna Science and Technology Co., Ltd

INDUSTRY